CN
Company overview
时迈药业
Mission-Driven
Innovation
CentryMed is a science-driven biopharmaceutical company committed to addressing global unmet medical needs through disruptive antibody innovation. We focus on developing first-in-class and best-in-class biologics that deliver real clinical impact for patients with cancer and autoimmune diseases.
Integrated R&D Ecosystem Across China and the U.S.
Leveraging dual-region advantages, we have built a full-cycle biologics R&D system—from antibody discovery to clinical
development. Our core R&D team has pioneered four proprietary platforms with global competitiveness:
时迈药业
Fully human IgM ultra-large antibody libraries & cross-species discovery (rodents, rabbits, primates)
时迈药业
H-BiTE platform：T-cell engaging bispecific antibodies (TCE)
时迈药业
Pro-BiTE platform： enzyme-activated tumor-specific TCE
时迈药业
Multifunctional TCE Platform with optimized druggability and modular design
These platforms empower us to generate a pipeline with high diversity, functional precision, and translational efficiency.
  • 时迈药业 时迈药业
    Robust Pipeline with Global First-in-Class Potential
    We have established a differentiated pipeline of 20+ antibody programs, including monoclonal, bispecific, and trispecific formats. Several first-in-class assets have entered clinical trials and demonstrated:
    Encouraging signals of efficacy in advanced solid tumors
    Excellent tolerability and safety profiles
    Clear potential to fill critical gaps in current treatment landscapes
  • 时迈药业 时迈药业
    International Talent and Scientific Leadership
    Our R&D team consists of globally experienced scientists, with leadership drawn from top U.S. academic institutions and biotech companies. Under expert guidance, we continuously optimize platform design and product strategy to stay ahead of innovation trends.
  • 时迈药业 时迈药业
    Recognition & Achievements
    CentryMed is recognized as one of China's most innovative biotech companies. Notable achievements include:
    2nd Prize, National "Chuangke China" Innovation Competition
    1st Prize, China Innovation & Entrepreneurship Competition, Zhejiang Division
    Outstanding Project, National Disruptive Technology Innovation Competition
    Recognized as a “Specialized and Innovative” SME in Zhejiang
    Named a Hangzhou Future Unicorn Company
  • 时迈药业 时迈药业
    Strong Financial Backing & Global Partnerships
    Since our founding in 2016, CentryMed has raised hundreds of millions of RMB across Series A to C funding rounds. We maintain strategic collaborations with top-tier global investors and are actively expanding our international footprint through:
    Licensing-out partnerships
    Co-development opportunities
    IPO and capital market readiness
Looking Ahead
We are advancing the industrialization and globalization of antibody therapeutics. Our focus remains
on translating breakthrough science into meaningful clinical outcomes, delivering value to patients,
partners, and investors worldwide.